Last reviewed 2026-04-20 · How we verify

Selzentry (MARAVIROC)

Selzentry works by blocking the CCR5 receptor on immune cells, preventing HIV from entering and infecting these cells.

Selzentry (Maraviroc) is a CCR5 Co-receptor Antagonist developed by ViiV Healthcare, targeting the C-C chemokine receptor type 5. It is a small molecule modality approved by the FDA in 2007 for the treatment of CCR5 Tropic Drug Resistant HIV Infection. As an off-patent medication, Selzentry is available from multiple generic manufacturers. Key safety considerations include its bioavailability of 23% and half-life of 12.8 hours. Commercially, Selzentry is available as a generic medication.

At a glance

Mechanism of action

Maraviroc is an antiviral drug [see Clinical Pharmacology (12.4) ].

Approved indications

• CCR5 Tropic Drug Resistant HIV Infection

Boxed warnings

• BOXED WARNING WARNING: HEPATOTOXICITY Hepatotoxicity has been reported with use of maraviroc tablets. Severe rash or evidence of a systemic allergic reaction (e.g., fever, eosinophilia, or elevated IgE) prior to the development of hepatotoxicity may occur. Patients with signs or symptoms of hepatitis or allergic reaction following use of maraviroc tablets should be evaluated immediately [see Warnings and Precautions ( 5.1 )]. WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning. • Hepatotoxicity has been reported which may be preceded by severe rash or other features of a systemic allergic reaction (e.g., fever, eosinophilia, or elevated IgE). ( 5.1 ) • Immediately evaluate patients with signs or symptoms of hepatitis or allergic reaction. ( 5.1 )

Common side effects

• Upper respiratory tract infections
• Dizziness
• Pyrexia
• Rash
• Cough
• Diarrhea
• Edema
• Influenza
• Esophageal candidiasis
• Sleep disorders
• Rhinitis
• Parasomnias

Drug interactions

• boceprevir
• conivaptan
• fosphenytoin
• mibefradil
• nefazodone
• nelfinavir
• nevirapine
• phenobarbital
• phenytoin
• posaconazole
• primidone
• rifabutin

Key clinical trials

• Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2,PHASE3)
• Antiviral Clinical Trial for Long Covid-19 (PHASE2)
• Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ... (PHASE1,PHASE2)
• This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction (PHASE2)
• Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
• Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes (NA)
• Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
• Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2,PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.